NO20091111L - Anvendelse av R(+)-alfa-(2,3-dimetoksyfenyl)-l-[2-(4-fluorfenyl)etyl]-4-piperidin-metanol for behandling av sovnforstyrrelser - Google Patents

Anvendelse av R(+)-alfa-(2,3-dimetoksyfenyl)-l-[2-(4-fluorfenyl)etyl]-4-piperidin-metanol for behandling av sovnforstyrrelser

Info

Publication number
NO20091111L
NO20091111L NO20091111A NO20091111A NO20091111L NO 20091111 L NO20091111 L NO 20091111L NO 20091111 A NO20091111 A NO 20091111A NO 20091111 A NO20091111 A NO 20091111A NO 20091111 L NO20091111 L NO 20091111L
Authority
NO
Norway
Prior art keywords
dimethoxyphenyl
fluorophenyl
ethyl
treatment
piperidine
Prior art date
Application number
NO20091111A
Other languages
English (en)
Inventor
Cesare Mondadori
Stephen M Sorensen
Janice M Hitchcock
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20091111L publication Critical patent/NO20091111L/no
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En fremgangsmåte for å behandle en pasient for en søvnforstyrrelse omfattende å administrere en effektiv mengde av R-(+)-a-(2,3-dimetoksyfenyl)-l-[2-(4-fluorfenyl) etyl-4-piperidinmetanol eller et farmasøytisk akseptabelt salt derav til en pasient som har behov for slik behandling.
NO20091111A 1998-08-28 2009-03-13 Anvendelse av R(+)-alfa-(2,3-dimetoksyfenyl)-l-[2-(4-fluorfenyl)etyl]-4-piperidin-metanol for behandling av sovnforstyrrelser NO20091111L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14313598A 1998-08-28 1998-08-28
PCT/US1999/017331 WO2000012090A1 (en) 1998-08-28 1999-07-29 THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS

Publications (1)

Publication Number Publication Date
NO20091111L true NO20091111L (no) 2001-04-25

Family

ID=22502745

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20010984A NO20010984L (no) 1998-08-28 2001-02-27 Anvendelse av R(+)-<alfa>-(2,3-dimetoksyfenyl)-1-[2-(4-fluorfenyl)etyl]-4-piperidinmetanol for behandling av sovnforstyrrelser
NO20091111A NO20091111L (no) 1998-08-28 2009-03-13 Anvendelse av R(+)-alfa-(2,3-dimetoksyfenyl)-l-[2-(4-fluorfenyl)etyl]-4-piperidin-metanol for behandling av sovnforstyrrelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20010984A NO20010984L (no) 1998-08-28 2001-02-27 Anvendelse av R(+)-<alfa>-(2,3-dimetoksyfenyl)-1-[2-(4-fluorfenyl)etyl]-4-piperidinmetanol for behandling av sovnforstyrrelser

Country Status (32)

Country Link
EP (2) EP1105132B1 (no)
JP (1) JP2002523460A (no)
KR (3) KR100735513B1 (no)
CN (1) CN1127954C (no)
AT (1) ATE249830T1 (no)
AU (1) AU764604B2 (no)
BG (2) BG65416B1 (no)
BR (1) BR9913242A (no)
CA (2) CA2341891C (no)
CZ (1) CZ300781B6 (no)
DE (2) DE69911436T2 (no)
DK (1) DK1105132T3 (no)
EA (1) EA003791B1 (no)
EE (1) EE04951B1 (no)
ES (1) ES2204146T3 (no)
HK (1) HK1040907B (no)
HR (2) HRP20010140A2 (no)
HU (1) HUP0202145A3 (no)
ID (1) ID29601A (no)
IL (2) IL141603A0 (no)
ME (1) MEP20308A (no)
MX (1) MXPA01002026A (no)
NO (2) NO20010984L (no)
NZ (1) NZ510083A (no)
PL (1) PL195022B1 (no)
PT (1) PT1105132E (no)
SK (1) SK284858B6 (no)
TR (1) TR200100670T2 (no)
TW (1) TWI233802B (no)
UA (1) UA74773C2 (no)
WO (1) WO2000012090A1 (no)
ZA (1) ZA200101466B (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099076A1 (en) 2000-05-25 2002-07-25 Richard Scheyer D. Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
CN1305871C (zh) 2002-07-19 2007-03-21 比奥维特罗姆股份公司 用于治疗与5－ht2a受体有关疾病的新哌嗪基－吡嗪酮衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169096A (en) 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
US4877798A (en) * 1987-11-23 1989-10-31 Merrell Dow Pharmaceuticals Inc. Treatment of fibromyalgia
DE3888340T2 (de) * 1988-01-21 1994-06-30 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
DE69105501T2 (de) * 1990-06-01 1995-04-13 Merrell Dow Pharma (+)-alpha-(2,3 dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinmethanol.
JPH05134149A (ja) * 1991-11-08 1993-05-28 Nippondenso Co Ltd 光半導体モジユール
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
US9702597B1 (en) 2016-02-18 2017-07-11 King Fahd University Of Petroleum And Minerals System and method for preventing absorbent crystallization in a continuously operating solar-powered absorption cooling system with hybrid storage

Also Published As

Publication number Publication date
HK1040907B (zh) 2004-04-02
HRP20010140A2 (en) 2002-02-28
MEP20308A (en) 2010-06-10
ID29601A (id) 2001-09-06
IL141603A (en) 2006-08-20
UA74773C2 (en) 2006-02-15
WO2000012090A1 (en) 2000-03-09
EE04951B1 (et) 2008-02-15
HRP20080389A2 (en) 2008-11-30
EP1105132A1 (en) 2001-06-13
KR20060023197A (ko) 2006-03-13
AU764604B2 (en) 2003-08-21
KR100735513B1 (ko) 2007-07-06
EP1105132B1 (en) 2003-09-17
DK1105132T3 (da) 2003-11-24
NZ510083A (en) 2003-08-29
CZ300781B6 (cs) 2009-08-12
JP2002523460A (ja) 2002-07-30
DE69911436T2 (de) 2004-07-01
CN1127954C (zh) 2003-11-19
MXPA01002026A (es) 2003-03-27
CA2629396A1 (en) 2000-03-09
EA200100201A1 (ru) 2001-08-27
BR9913242A (pt) 2001-05-15
NO20010984L (no) 2001-04-25
HK1040907A1 (en) 2002-06-28
DE69941134D1 (de) 2009-08-27
DE69911436D1 (de) 2003-10-23
TR200100670T2 (tr) 2001-06-21
HUP0202145A2 (hu) 2003-01-28
NO20010984D0 (no) 2001-02-27
PT1105132E (pt) 2004-02-27
EA003791B1 (ru) 2003-10-30
TWI233802B (en) 2005-06-11
SK2692001A3 (en) 2001-07-10
KR20010073026A (ko) 2001-07-31
PL195022B1 (pl) 2007-08-31
BG109953A (en) 2007-12-28
ES2204146T3 (es) 2004-04-16
KR20060057029A (ko) 2006-05-25
EE200100122A (et) 2002-06-17
SK284858B6 (sk) 2006-01-05
EP1362589B1 (en) 2009-07-15
BG65416B1 (bg) 2008-07-31
KR100682799B1 (ko) 2007-02-15
ATE249830T1 (de) 2003-10-15
CA2341891C (en) 2009-05-12
CZ2001726A3 (en) 2001-06-13
BG105289A (en) 2001-11-30
CA2341891A1 (en) 2000-03-09
AU5135999A (en) 2000-03-21
HUP0202145A3 (en) 2003-02-28
EP1362589A1 (en) 2003-11-19
ZA200101466B (en) 2002-05-21
PL346342A1 (en) 2002-02-11
CN1315861A (zh) 2001-10-03
IL141603A0 (en) 2002-03-10
KR100764532B1 (ko) 2007-10-09

Similar Documents

Publication Publication Date Title
FI925342A (fi) Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi
IL178745A0 (en) Methods for treatment and management of scleroderma using 4-(amino)-2(2,6-dioxo(3-piperidyl))-isoindoline -1,3-dione
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
DK0998287T3 (da) Anvendelse af levobupivacain
DK0946162T3 (da) Anvendelse af p-aminophenol-derivater til fremstilling af farmaceutiske præparater, som er nyttige til behandlingen af neurodegenerative sygdomme
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
AR006281A1 (es) Utilizacion de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4- piperidinometanol o sus sales de adicion de acidos farmaceuticamenteaceptables en el tratamineto de trastornos depresivos y trastornos bipolares
NO20091111L (no) Anvendelse av R(+)-alfa-(2,3-dimetoksyfenyl)-l-[2-(4-fluorfenyl)etyl]-4-piperidin-metanol for behandling av sovnforstyrrelser
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
NO20042758L (no) Fremgangsmate for behandling av en pasient som krever analgesi.
PE43795A1 (es) Compuesto neuroprotector
DK0871446T3 (da) Anvendelse af eliprodil til fremstilling af et lægemiddel til behandling af ischaemiske sygdomme i nethinden eller den optiske nerve
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
FI20010233A0 (fi) Menetelmä sydämen vajaatoiminnan hoitoon
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk
YU15301A (sh) PRIMENA R (+)- alfa-(2,3-DIMETOKSIFENIL)-1-[2-(4-FLUOROFENIL) ETIL] -4-PIPERIDINMETANOLA ZA LECENJE POREMEĆAJA SPAVANJA
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.
ECSP992840A (es) Procedimiento para tratar la insuficiencia cardiaca
UA26886C2 (uk) Солі 1,3-діарил-4,5-поліметилеhімідазолію, що виявляють аhальгезуючу активhість

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application